Gene Therapy for AIDS Using Retroviral Mediated Gene Transfer to Deliver HIV-1 Anti-Sense TAR and Transdominant Rev Protein Genes to Syngeneic Lymphocytes in HIV-1 Infected Identical Twins

Inclusion Criteria

INCLUSION CRITERIA:

- An identical twin pair, one of whom is seropositive for HIV-1, the other twin
seronegative, by standard ELISA and Western blot testing.

- Patients with Kaposi's sarcoma limited to the skin and/or mucous membranes are
eligible for this study, but must not have received any systemic therapy for

- KS within 4 weeks prior to entry. The diagnosis of KS must have been confirmed by
biopsy.

- Free from serious psychological or emotional illness and able to provide written
informed consent.

- Anticipated survival greater than 3 months.

- 18 years of age or older.

- Treatment with FDA-approved and/or expanded access antiretroviral agent(s) for
patients with baseline CD4 counts below 500 cells/mm(3). Patients with baseline CD4
counts above 500 cells/mm(3) are eligible to receive cell therapy on this protocol,
but must be treated with antiretroviral therapy if evidence of significant and
persistent viral activation occurs in association with a cell infusion. "Significant
and persistent viral activation" is defined as a 50 percent or greater increase above
baseline in any virologic parameter for at least 2 consecutive weeks.

- Recipient's CD4 count greater than 50 cells/mm(3).

- Recipient and Donor willing to have samples stored and undergo HLA testing.

EXCLUSION CRITERIA (Donor and Recipient):

- Lymphomas.

- Unwillingness to comply with current NIH Clinical Center guidelines concerning
appropriate notification of all current sexual partners of an individual regarding
his or her HIV-1 positive sero-status and the risk of transmission of HIV-1
infection.

- Recent history of substance abuse unless evidence is provided of an ongoing
therapeutic intervention (i.e. medical therapy or counseling) to control such abuse.

- Pregnant at entry or unwillingness to practice barrier birth control or abstinence
during the study.

- No experimental therapy within 4 weeks of study participation. Antiretroviral agents
available on an FDA-sanctioned, expanded access basis are permitted.

EXCLUSION CRITERIA (Donor):

- Untreated or inadequately treated medical condition (e.g., cardiopulmonary disease,
acute infection) which, in the judgement of the Principal Investigator, precludes
apheresis.

- Serologic positivity for Epstein Barr virus, Cytomegalovirus, Hepatitis B or
Hepatitis C, if and only if the recipient twin tests seronegative for the
corresponding virus.